Showing results (151-160 of 1,598) with videos related to
Sort By:
Pageof 160
Cancer Journal (Sudbury, Mass.)|November 22, 2016
The Importance of Biopsy in the Era of Molecular MedicineEtay Ziv, Jeremy C Durack, Stephen B SolomonCancer Journal (Sudbury, Mass.)|October 15, 2009
Lessons to be learned from 25 years of research investigating psychosocial interventions for cancer patientsAnne Moyer, Sarah K Knapp-Oliver, Stephanie J Sohl, et al.Cancer Journal (Sudbury, Mass.)|January 24, 2017
Novel Checkpoints and Cosignaling Molecules in Cancer ImmunotherapyIulia Giuroiu, Jeffrey WeberCancer Journal (Sudbury, Mass.)|January 24, 2017
Adoptive Cell Therapy for Metastatic MelanomaEfrat Merhavi-Shoham, Orit Itzhaki, Gal Markel, et al.Cancer Journal (Sudbury, Mass.)|January 24, 2017
Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic MelanomaShelly A Christiansen, Shaheer Khan, Geoffrey T GibneyCancer Journal (Sudbury, Mass.)|January 24, 2017
Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern EraBenjamin Izar, Meredith M Regan, David F McDermottCancer Journal (Sudbury, Mass.)|March 22, 2019
Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled AnalysisAndreas Seeber, Georges Chahine, Fadi Nasr, et al.Cancer Journal (Sudbury, Mass.)|October 15, 2009
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug developmentTatiana Vidaurre, Julia Wilkerson, Richard Simon, et al.Cancer Journal (Sudbury, Mass.)|October 15, 2009
Stable disease is a valid end point in clinical trialsAnthony W TolcherCancer Journal (Sudbury, Mass.)|October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug developmentDaniel S W Tan, George V Thomas, Michelle D Garrett, et al.Pageof 160